FDA could see several structural changes to speed product review pathways under legislation being developed by Sen. Kay Hagan.
The North Carolina Democrat’s Transforming the Regulatory Environment to Accelerate Access to Treatments Act also would mandate a fixed six-year term for
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?